Merck appointed Paul J. Diaz as a member of the board of directors
On October 13, 2026 Merck & Co., Inc. announced that Paul J. Diaz, managing partner of Cressey & Company, will join the board of directors on November 1, 2026, increasing the board to 14 members; he will serve on the audit and research committees and will receive standard compensation without conflicting agreements.
Key points
- Merck announced that Paul J. Diaz, managing partner of Cressey & Company, will join the board of directors on November 1, 2026, raising the board to 14 members.
- Chief executive officer and chairman Rob Davis said, “We are pleased to welcome Paul Diaz to our board; his broad healthcare experience will be a valuable contribution.”
- The appointment is not indicative of any future strategic changes or improvement in the company’s financial performance, and the compensation follows the usual terms for all independent directors and does not signal any special benefits or risks.
What happened
Merck announced that Paul J. Diaz, managing partner of Cressey & Company, will join the board of directors on November 1, 2026, raising the board to 14 members. The director will sit on the Audit Committee and the Research Committee. As per company practice, he will receive compensation as an independent director and has no arrangements or relationships that would require disclosure under Item 404(a) of Regulation S‑K.
Company explanation
Chief executive officer and chairman Rob Davis said, “We are pleased to welcome Paul Diaz to our board; his broad healthcare experience will be a valuable contribution.”
What this does not mean
The appointment is not indicative of any future strategic changes or improvement in the company’s financial performance, and the compensation follows the usual terms for all independent directors and does not signal any special benefits or risks.
Original sources
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow Merck
A notification in your browser or on your phone when we publish about Merck. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
